Supportive and Preventive Medicine

2006;26(4):452-460.

https://doi.

org/10.1592/phco.26.4.452

Ley EJ, Brown CVR, Moore EE, et al. Updated guide-

lines to reduce venous thromboembolism in trauma

patients: a Western Trauma Association critical decisions

algorithm. J Trauma Acute Care Surg. 2020;89(5):971-

981. https://doi.org/10.1097/ta.0000000000002830

Linkins LA, Dans AL, Moores LK, et al. Treatment

and prevention of heparin-induced thrombocytopenia:

Antithrombotic Therapy and Prevention of Thrombosis,

9th ed: American College of Chest Physicians

Evidence-Based Clinical Practice Guidelines. Chest.

2012;141(2 suppl):e495S-e530S. https://doi.org/10.1378/

chest.11-2303

Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing fre-

quency of unfractionated heparin thromboprophylaxis:

a meta-analysis. Chest. 2011;140(2):374-381. https://doi.

org/10.1378/chest.10-3084

Reynolds PM, Van Matre ET, Wright GC, et al.

Evaluation of prophylactic heparin dosage strategies and

risk factors for venous thromboembolism in the criti-

https://doi.org/10.1002/phar.2212

Sachdeva A, Dalton M, Amaragiri SV, Lees T.

Graduated compression stockings for prevention of

deep vein thrombosis. Cochrane Database Syst Rev.

2014;(12):CD001484. https://doi.org/10.1002/14651858.

cd001484.pub3

Saugel B, Phillip V, Moessmer G, Schmid RM, Huber

W. Argatroban therapy for heparin-induced throm-

bocytopenia in ICU patients with multiple organ

2010;14(3):R90. https://doi.org/10.1186/cc9024

Shorr AF, Williams MD. Venous thromboembolism in

critically ill patients. Observations from a randomized

trial in sepsis. Thromb Haemost. 2009;101(1):139-144.

Sikes L, Charles K, Antigua A, Patel R, Imboywa S,

Cherian P. Anti-factor Xa level monitoring for enoxa-

parin prophylaxis and treatment in high-risk patient

groups. HCA Healthc J Med. 2023;4(2):105-109. https://

doi.org/10.36518/2689-0216.1464

Wahby KA, Riley LK, Tennenberg SD. Assessment of

an extended interval fondaparinux dosing regimen for

venous thromboembolism prophylaxis in critically ill

patients with severe renal dysfunction using antifactor Xa

doi.org/10.1002/phar.2014

Yorkgitis BK, Berndtson AE, Cross A, et al. American

Association for the Surgery of Trauma/American College

of Surgeons-Committee on Trauma clinical protocol for

inpatient venous thromboembolism prophylaxis after

trauma. J Trauma Acute Care Surg. 2022;92(3):597-604.

https://doi.org/10.1097/ta.0000000000003475

End-of-Life Care

Brody H, Campbell ML, Faber-Langendoen K, Ogle

KS.

Withdrawing

intensive

life-sustaining

treat-

ment—recommendations for compassionate clinical

management. N Engl J Med. 1997;336(9):652-657.

https://doi.org/10.1056/nejm199702273360910

Chan JD, Treece PD, Engelberg RA, et al. Narcotic and

benzodiazepine use after withdrawal of life support:

association with time to death? Chest. 2004;126(1):286-

293. https://doi.org/10.1016/s0012-3692(15)32925-1

Durán-Crane A, Laserna A, López-Olivo MA, et

al. Clinical practice guidelines and consensus state-

ments about pain management in critically ill

Med.

2019;47(11):1619-1626.

https://doi.org/10.1097/

ccm.0000000000003975

Kamal AH, Maguire JM, Wheeler JL, Currow DC,

Abernethy AP. Dyspnea review for the palliative care

professional: treatment goals and therapeutic options. J

Palliat Med. 2012;15(1):106-114. https://doi.org/10.1089/

jpm.2011.0110

Laserna A, Durán-Crane A, López-Olivo MA, et al. Pain

management during the withholding and withdrawal of

life support in critically ill patients at the end-of-life:

Med.

2020;46(9):1671-1682.

https://doi.org/10.1007/

s00134-020-06139-7

Simon ST, Higginson IJ, Booth S, Harding R, Bausewein

C. Benzodiazepines for the relief of breathlessness in

advanced malignant and non-malignant diseases in

adults. Cochrane Database Syst Rev. 2010;(1):CD007354.

https://doi.org/10.1002/14651858.cd007354.pub2

Treece PD, Engelberg RA, Crowley L, et al. Evaluation

of a standardized order form for the withdrawal of

2004;32(5):1141-1148.

https://doi.org/10.1097/01.

ccm.0000125509.34805.0c